Zura Bio Limited (Class A) (ZURA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ZURA scores 29 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars each carry a maximum of 20 points. Fundamental Cash Engine scores 5/20, reflecting ROIC of -35% and an FCF yield of -17.51%. Whale 13F Flow scores 5/20, covering institutional accumulation and options positioning. Insider Conviction scores 3/20, covering SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 6/20, reflecting a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10/20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the pillar profile indicates that the weakest areas are cash generation and insider conviction, while the balance sheet is the relatively stronger component. Upside drivers would have to come from a reversal in cash burn, which the source data does not show. Valuation tradeoffs are difficult to assess directly because P/E, EV/EBITDA, and EPS are not available in source data. The rating's verdict is negative on a forensic and risk basis, and the data presented here is educational rather than a recommendation.

Zura Bio Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). Per the profile, the market capitalization is $0.4B. Per the SEC financials, reported revenue is $0.0M in each of the listed fiscal years. Not available in source data for product lines, customer base, or revenue model detail.

Per the SEC financials, operating and net losses are reported in each period, with FY 2025 showing the largest operating loss in the table. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the Roarable RQD rating, Debt/Equity is 0.5. Reported cash declined from $176.5M in FY 2024 to $109.4M in FY 2025.

• Yahoo Finance: Guggenheim top-pick headline (YELLOW, MARKET WIRE).
• TradingView: Estimates headline (YELLOW, MARKET WIRE).
• Investing.com UK: Form 8-K headline for 27 October (YELLOW, MARKET WIRE).
• Business Wire: Inducement grants under Nasdaq Listing Rule 5635(c)(4) (YELLOW, MARKET WIRE).
• Quiver Quantitative: Third-quarter 2026 net loss report (RED, RISK WATCH).
• scanx.trade: Prospectus to offer up to $700 million in securities (YELLOW, MARKET WIRE).

The single RED item is the Quiver Quantitative loss report, flagged as RISK WATCH. The prospectus item for up to $700 million in securities is relevant to dilution considerations, though the source data does not state how the proceeds would be used. Per the Butterfly Supply-Chain Graph, there are no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The investor should note that the sector is Health Care and the industry is Biotechnology: Biological Products (No Diagnostic Substances), but the source data does not map specific suppliers, customers, or peer correlations.

• What is the company's revenue path, given reported revenue of $0.0M across the listed periods?
• How does the company plan to fund operations, given reported FY 2025 free cash flow of $-64.9M and cash declining to $109.4M?
• What are the intended uses of proceeds from the up-to-$700 million securities offering referenced in the news wire?
• What is the status of the clinical or commercial pipeline, which the source data does not describe?
• What is the analyst consensus, and who are the institutional and insider holders, given that these sections are not available in source data?